Economic Practices and Financial Performances of Pharma Company in Rural Areas

Main Article Content

Dr Sarika Keswani, Luigi Pio Leonardo Cavaliere, Dr P.S. Venkateswaran, Iskandar Muda, Dr K.Bhavana Raj Dr Rupa Khanna, S. Suman Rajest, R. Regin

Abstract

In the heart of Europe, rural areas demanded healthcare from unskilled and sometimes improperly controlled pharmaceutical stores, which were worried about the quality and public health consequences of the goods and services rendered. The study sought to explain consumer relations in a rural retail drug market regarding the systemic conduct-performance model and the possibilities for future policy actions for better access to and secure medications. The research was carried out. Data were collected in 2012 in the Benue State Local Government District, in the northern UK, for more than 9 months from a survey of patent medicine vendors and drug purchasers. Drug sellers and prescription users were informed using semi-structured questionnaires, comprehensive interviews and comprehensive observations of purchases. In-depth interviews and the associated documented evidence gathered and analyzed were also conducted with key regional and national substance enforcement officials. To explain business performance and fair usage, the data analysis centred on the interactions between the market system and supplier behaviour, customer and regulatory character. The study showed that patent-medicine suppliers were a significant source of primary ambulatory health treatment for citizens of the local governments. Drug sellers have been named credible suppliers of several medications sold at comparatively more reasonable rates and satisfy market criteria. Nevertheless, there have been some industry shortcomings, such as inadequate care efficiency due to insufficient understanding of diseases and medicinal goods and thus ineffective prescribing and dissemination procedures. Inappropriate and insufficient regulatory regime, which has contributed to extensive regulatory abuses, has also been shown by ineffectual legislation. Regulative strategies must be contextually applicable, manufacturers must be educated and financial and market benefits provided. Customers must acquire usable and timely clinical knowledge for informed decisions against the backdrop to accomplish a desirable public health goal of sustained increases in the quality of goods and services in patent medicine vendors.


 

Article Details

Section
Articles